By

Psilocybin is the best-known active ingredient in “magic mushrooms,” but in the body, it is primarily the metabolite psilocin that is active. For a therapist interested in psychedelic-assisted therapy, basic knowledge regarding dosage, metabolism, and safety is important. Not to start “prescribing” themselves, but to better interpret research results, manage expectations, and conduct effective harm reduction conversations.

In this article, we discuss a small pharmacokinetic study in healthy volunteers. The focus was not on therapeutic outcomes, but on how the body responds to increasing oral doses of psilocybin: how quickly it is metabolized, how long psilocin remains present, and what variation can be expected. As a source, we use the summary of this study as described at Trip forum.

Why pharmacokinetics is relevant to a therapist

“Pharmacokinetics” concerns the uptake, metabolism, distribution, and excretion of a substance. For psilocybin, this is more than a technical detail. It influences, among other things:

• Timing: when effects usually arise, peak, and subside.

• Dosage: how a higher dose typically translates to higher exposure in the blood.

• Variation: why two people can still react differently to the same dose.

• Safety frameworks: which physical parameters are monitored in studies and why “set and setting” cannot be viewed separately from physical monitoring.

Important: pharmacokinetics does not directly indicate therapeutic efficacy or suitability for individual clients. It is one building block alongside psychology, context, counseling, screening, and aftercare.

From psilocybin to psilocin: rapid conversion

The study discussed showed that intact psilocybin was not detectable in plasma or urine. This suggests that after oral ingestion, psilocybin is rapidly converted into psilocin, the substance primarily responsible for the psychoactive effects.

For a therapist, this is conceptually useful: in conversations about “psilocybin,” the focus in the body quickly shifts to psilocin. This helps to understand research reporting blood levels or half-lives, and to explain why the effect profile can differ from what people expect based solely on ingested milligrams.

At the same time, “not demonstrable” depends on the measurement method and the timing of the measurements. It does not mean that literally no psilocybin was present, but rather that in this setup, it was not measured above the detection limit.

Dose escalation in the study: what exactly was done?

The researchers conducted an open-label dose escalation study in 12 healthy adults. They received three oral doses in a controlled setting: 0.3 mg/kg, 0.45 mg/kg, and 0.6 mg/kg, with approximately one month between sessions.

It is striking to therapists that not only “a capsule” was administered. Participants received 6 to 8 hours of preparation beforehand, and were monitored for 24 hours after each session. This underscores how seriously research teams take context, guidance, and observation, even when the primary outcome is pharmacokinetics rather than therapeutic result.

The researchers also collected blood and urine samples over a 24-hour period and analyzed them using LC-MS/MS (a sensitive laboratory method). This allowed them to estimate parameters such as clearance and half-life.

Linear pharmacokinetics: what does that mean in practice?

Within the investigated dose range (approximately a doubling), the pharmacokinetics of psilocin proved to be linear. Simplified: if you increase the dose, blood exposure to psilocin increases approximately proportionally.

For a therapist, this does not mean that the subjective experience also increases “linearly.” On the contrary, psychedelic experiences can feel disproportionate due to psychological processes, set and setting, and sensitivity. However, pharmacokinetic linearity does provide a point of reference: higher doses lead, on average, to higher psilocin exposure, without any indication within this range of, for example, unexpected accumulation.

The nuance remains that this was found in a small group of healthy adults and within a limited dose range. Outside that range, or in other populations, the outcome may be different.

Half-life around 3 hours and variation between people

The average elimination half-life of psilocin was approximately 3 hours (with a standard deviation of 1.1 hours). A half-life is the time in which the concentration in the blood halves on average. This helps to understand why the “tail” of the experience can continue for hours, while the peak has already passed.

In some participants, the researchers observed a prolonged elimination phase. They suggest that this may be consistent with the hydrolysis of psilocin glucuronide, a metabolite that can contribute to a longer presence of psilocin. For a therapist, this is primarily an indication that there may be biological explanations for longer after-effects in some people, independent of psychological integration processes.

In addition, variation in psilocin clearance was found not to be well predicted by body weight. This is relevant because weight is often intuitively viewed as a “logical” factor in dosing. This result supports why many modern studies use fixed doses, but it does not mean that weight is never relevant. It only means that in this dataset, it was not a strong predictor of differences in clearance.

Fixed dose versus mg/kg: why 25 mg comes up frequently

The authors used their parameters to simulate that a fixed oral dose of 25 mg would provide exposure approximately comparable to 0.3 mg/kg. This is practical, because many later studies work with fixed doses instead of weight-based dosing.

For therapists, it is useful to know where such figures come from: not from “what feels comfortable,” but from a combination of previous experience, safety frameworks, and pharmacokinetic substantiation. At the same time, it remains a population-level approach. It says nothing about what would be appropriate or safe for one specific person, and certainly not outside a research context.

Safety: what this study can and cannot say

In this small study, no serious physical or psychological side effects occurred during the sessions or within 30 days after the doses, even at 0.6 mg/kg. That is reassuring within this setting, but it is not proof that psilocybin is “safe for everyone” or in every context.

What we cannot deduce from this:

• How people with psychiatric disorders, trauma-related complaints, or increased vulnerability respond.

• What the effect is when using certain medication or in the case of complex somatic conditions.

• How risks play out outside a controlled setting with preparation and monitoring.

A therapist can make these types of limitations explicit. This is not a fear of the unknown, but professional nuance: research with healthy volunteers is a first step, not the end point.

Harm reduction and professional frameworks

In the Netherlands, psilocybin and psilocybin-assisted therapy are discussed in various contexts. What is important for therapists is that, where MDMA is concerned, psychedelic sessions should currently only be discussed within scientific research or in practice via a harm reduction context. For psilocybin, too, the legal and organizational context determines what is and is not responsible, and supervision in studies is highly protocolled.

A harm reduction approach means, among other things: good psychoeducation, attention to set and setting, a sober risk assessment, and the normalization of aftercare and integration. Without medical claims, without guarantees, and without pretending that one substance “solves the trauma”.

Professionals wishing to explore guided sessions or the way in which trajectories are structured in practice can read more about psilocybin therapy. This is not a substitute for training, supervision, or clinical guidelines, but it can help to better understand the landscape.

Conclusion

This pharmacokinetic study shows that oral psilocybin is rapidly converted into psilocin in healthy adults, that psilocin exhibits linear pharmacokinetics within a limited dose range, and that the average half-life is around 3 hours, with noticeable variation between individuals. For a therapist, this is particularly valuable background knowledge: it supports realistic explanations regarding timing, variation, and why fixed doses are often used in research.

Anyone wishing to explore a path within the framework of guidance and harm reduction can orient themselves by signing up for a session, with the understanding that the exact possibilities depend on the context and that there are no guarantees regarding outcomes.